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Abstract
Background: Global Initiative Strategy for Asthma Management (GINA) is poorly applied in
undeveloped and developing countries. The current study examined the effects of applying GINA
guidelines on treatment efficacy in asthmatic patients in Iran.
Methods: Twenty four asthmatic patients (usual care group) were treated as usual and 26 patients
(intervention group) according to the GINA for 2 months. Asthma symptom score, asthma
severity, frequency of symptoms/week and wheezing were recorded at the beginning (first visit),
one month after treatment (second visit), and at the end of the study (third visit). Pulmonary
function tests (PFTs) were performed by spirometry, and the patients' use of asthma drugs and
their symptoms were evaluated, at each visit.
Results: Asthma symptoms, frequency of symptoms/week, chest wheezing, and PFT values were
significantly improved in the intervention group at the second and third visits compared to first visit
(p < 0.001 for all measures). In addition, exercise induced cough and wheeze were significant
improved in the third visit compared to the second visit in this group (p < 0.01 for both measures).
In the second and third visits all symptoms were significantly lower, and PFT values higher, in the
intervention group compared to the usual care group (p < 0.005 to p < 0.001). In the usual care
group, there were only small improvements in some parameters in just the second visit (p < 0.01
for all measures). The use of asthma drugs was unchanged in the usual care group and significantly
reduced in the intervention group (p < 0.01) by the end of the study.
Conclusion: Adoption of GINA guidelines improves asthma symptoms and pulmonary function in
asthmatic patients in Iran.
Background
Asthma is known as a chronic disease, and epidemiologi-
cal studies indicate that its prevalence is increasing world-
wide [1]. The reason for the rise in prevalence is not clear
[2]. Asthma affects over 10% of children and over 5% of
adults in many European countries, and imposes a large
burden on health services provision [1]. In Iran asthma
affects 4.2% of children [3] and 2.8% of adults [4]. Opti-
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mal management of asthma requires appropriate drug
administration, avoidance of exacerbating factors, and
patient education [5].
There is still debate about how asthma should be treated
pharmacologically and at what stage anti-inflammatory
therapy should be introduced [6]. Low use of as-required
beta2-agonist (less than once a day), and using drugs with
low risk of side-effects are important goals of asthma treat-
ment. However, sensitive indices of asthma severity
including quality-of-life measurements, measurement of
bronchial reactivity, or a measure of airway inflammation
may be accessible to some types of health care services in
developing countries. Lack of easily accessible guidelines,
some medications and perhaps spirometry in developing
countries making it difficult to assess asthma severity and
achievement of optimal treatment. Thus asthma symp-
toms are often underestimated, leading to inadequate
therapy [3].
The goals of asthma treatment have been significantly
altered in the new guidelines [5]. More attention is paid to
patient satisfaction placing greater emphasis on quality of
life goals and on the partnership between the patient and
provider rather than the provider simply telling the
patient what to do [6]. We have previously shown that
asthmatic patients in Iran benefit poorly from asthma
education programs designed to teach them to avoid risk
factors and to administer drugs correctly (specially with
inhalers) [3,4]. Other forms of education (e.g., proper use
of inhalers, avoidance of aggravating factors, regular PEF
measurements) did lead to significant improvement in
asthma management [7-9].
In the present study, we examined the effect of adopting
the Global Initiative Strategy for Asthma Management
(GINA) to treat asthma patients in Iran on asthma symp-
toms (including wheezing) and spirometric measures of
pulmonary function.
Methods
Patients
Fifty asthmatic patients were recruited from the Asthma
Clinic, Ghaem Medical Centre, Mashhad University of
Medical Sciences and divided randomly into a usual care
group (24 patients, 15 female, aged 45 ± 11 years, height
159 ± 8 cm) and a intervention group (26 patients,16
female, aged 40 ± 11 years, height 162 ± 9 cm). Inclusion
criteria were: 1) previously diagnosed with asthma by a
physician. 2) Two or more of the following symptoms:
recurrent wheeze, cough or chest-tightness at rest; noctur-
nal or early morning wheeze, cough or chest-tightness;
and wheeze or cough during exercise, 3) FEV1 and PEF
less than 80% predicted values, 4) No history or symp-
toms of cardiovascular or other respiratory diseases that
required treatment (excluding the common cold). The
studied patients had moderate to severe asthma according
to GINA guidelines [5]. The protocol was approved by the
Ethics Committee of our institution, and each subject
gave informed consent. The study was carried out during
the Spring and Summer of 2005.
Treatment duration and administered drugs
Each patient was treated for a period of two months and
was visited and evaluated three times over this period. The
treatment regimen of all patients included inhaled corti-
costeroid, mostly beclomethasone dipropionate (400–
1400 μg depending on disease severity) and in some cases
fluticasone dipropionate (500 μg). The treatment regimen
included oral corticosteroids in 64% of the patients.
Ninety-seven percent of patients received methyl xanthine
and 58% received inhaled salbutamol. None of the
patients had oral β-agonist drugs as part of their treatment
regimen. Very few patients were under an acceptable ther-
apeutic regimen for asthma at the start of the study
according to GINA guidelines [5].
Protocol
The intervention group was treated according to the GINA
guidelines [5]. They were educated regarding the; 1)
avoidance of risk factors for aggravation of the disease, 2)
correct inhalation technique for using inhaler drugs, 3)
regular usage of administration drugs. 3) recording of
number and time of asthma attack. The treatment regi-
men of this group was adjusted and tapered according to
symptoms score and PFT values. However, usual care
group were treated by respirologist in the usual manner.
The study was performed in single blind manner. Medical
examination was performed and asthma symptoms taken
at the beginning, middle (one month after starting the
study) and end of the study for each patient. Asthma
symptom score was counted according to Table 1[7,8,10].
The degree of wheezing was considered between 0 – 3 as
follows: no wheezing = 0, hardly heard wheezing = 1,
moderate wheezing = 2, and loud wheezing = 3.
Pulmonary function tests were also measured in the
beginning and at the end of the study using a spirometer
with a pneumotachograph sensor (Model ST90, Fukuda,
Sangyo Co., Ltd. Japan). Prior to pulmonary function test-
ing, the required manoeuvre was demonstrated by the
operator, and subjects were encouraged and supervised
throughout test performance. Pulmonary function testing
was performed using the acceptability standards outlined
by the American Thoracic Society (ATS) with subjects in a
standing position and wearing nose clips [11]. All tests
were carried out between 1000 and 1700 hours. Pulmo-
nary function tests were performed three times in each
subject. The highest level for forced vital capacity (FVC),
forced expiratory volume in one second (FEV1), peakBMC Pulmonary Medicine 2008, 8:26 http://www.biomedcentral.com/1471-2466/8/26
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expiratory flow (PEF), maximal mid expiratory flow
(MMEF), maximal expiratory flow at 75%, 50% and 25%
of the FVC (MEF75, MEF50 and MEF25 respectively) were
taken independently from the three curves.
Data analysis
Based on the prevalence of asthma in Iran, using the PPS
sampling method, it was calculated that a minimum of 15
subjects in each group would be needed to detect a 4% dif-
ference with an α error of 1% and a power of 95%. However,
24 patients as usual care and 26 patients as intervention
group were studied. The data of asthma symptom score,
chest wheeze, and frequency of occurrence of symptoms/
week were expressed as mean± SEM and PFT values and
those of height and age as mean± SD. All data were com-
pared between the beginnings, middle and the end of the
study (three visits) using repeated measure analysis of vari-
ance (ANOVA) and between usual care and intervention
groups using unpaired "t" test. Due to the time-group inter-
action of the data, multivariate method (repeated measure-
ments) was not applied for comparison of the beginnings,
middle and the end of the study (three visits) between usual
care and intervention groups. The difference of percentage of
patients using each type of drug between each two visits was
tested by Chi-square testing on 2 × 2 contingency tables. Sig-
nificance was accepted at p < 0.05.
Results
Asthma symptoms
All symptom scores of asthmatic patients treated accord-
ing to GINA guidelines (intervention group) were
improved even after 1 month's treatment (second visit)
and at the end of the study (third visit, (p < 0.001 for all
cases). In addition, exercise induced cough was signifi-
cantly improved in the third visit compared to the second
visit in this group (p < 0.01), (Fig. 1b). However, in the
usual care group there was a small improvement in some
symptoms between the first and second visits only (p <
0.01 for all cases), (Fig. 1a). Asthma symptoms were not
different between the intervention and usual care groups
at the start of the study and were significantly reduced in
the intervention group compared to the usual care sub-
jects at the second and third visits (p < 0.005 to p < 0.001),
(Table 2).
Severity of asthma and wheezing
Asthma severity score, frequency of occurrence of asthma
symptoms/week and chest wheezing were also control
improved at the second and third visit in the intervention
group (p < 0.001 for each measure). The symptoms/week
continued to control improve significantly between the
second and third visits in this group (p < 0.01), (Fig. 2b).
In the usual care group only chest wheezing was signifi-
cantly control improved at the second visit than at the first
visit (p < 0.05) but were not significantly difference
between third and first visits (Fig. 2a). While at the begin-
ning of the study, there was no significant difference in
asthma severity score, frequency of asthma symptoms/
week and chest wheezing between the usual care and
intervention groups, in second and third visit all parame-
ters in the intervention group became significantly lower
than usual care group (p < 0.001 for all cases), (Table 2).
Table 1: The criteria for asthma severity score
Symptom Frequency Score
Night wheezing None 0
Sleeping well with a little wheezing 1
Waking once at night 2
Waking most of night 3
Night cough None 0
Sleeping well with a little cough 1
Waking once at night 2
Waking most of night 3
Exercise cough and wheezing No existence during strong exercise 0
Existence only during strong exercise 1
Existence during climbing stairs 2
Existence during ordinary activity 3
Morning cough, tightness, and wheezing None 0
Existence in case of exertion 1
Mild symptoms without exertion 2
Waking at the morning due to symptoms 3
Day time cough, tightness, and wheezing None 0
Once a day 1
Two or more times a day 2
Affecting day time activity 3
Total score 16BMC Pulmonary Medicine 2008, 8:26 http://www.biomedcentral.com/1471-2466/8/26
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Pulmonary function tests
All PFT variables were abnormally low in both groups of
patients at the beginning of the study (41.38 ± 15.77 to
61.50 ± 11.77 percent predicted values). In the intervention
group, all PFT values were significantly higher in the second
visit (p < 0.01) and the third visit (p < 0.001) compared to
the first (Fig 3b). Since PFTs were not significantly different
between the second and third visits in this group, the
improvement occurred primarily within 1 month. In the
usual care group, only FVC was significantly improved in the
second visit compared to the first visit (p < 0.05), (Fig. 3a).
While there was no significant difference in PFT variables
between usual care and intervention groups at the beginning
of the study, all PFT variables were significantly higher in the
intervention group at the second and third visits (p < 0.001
for all measures), (Table 3).
Treatment regimen and inhaler using technique
The use of inhaled and oral β-agonists, inhaled and oral
corticosteroid, and oral theophylline was decreased at the
end of the study for the intervention group; the propor-
tion of patients employing the correct technique when
using their inhaler increased from 31% (visit 1) to 100%
(visit 3) in this group. No obvious changes noted for the
usual care group with regard to drug use or proportion of
patients employing the correct technique when using
their inhaler (table 4). In Table 5, number and percentage
of two groups of asthmatic subjects under combination
therapy and different type of drugs used and percentage of
patients using each type of drug was presented.
Discussion
The results of the present study showed greater improve-
ment in asthma symptoms and in pulmonary function of
patients treated according to GINA guidelines comparing
to a usual care group receiving usual treatment.
According to the guidelines the main aims of asthma
management are to control symptoms maintain pulmo-
nary function close to a normal level and maintain nor-
mal physical activity levels [5]. In the present study
significantly greater improvements in PFT values were
noted for the intervention group after only a short period
of treatment according to GINA guidelines; the PFT values
improved by more than 15% becoming close to predicted
normal values in just 2 months oeriod. The asthma symp-
tom scores also improved more in the intervention group,
these patients were almost symptom free at the end of the
study. Asthma severity improved from a moderate-severe
persistent category to an intermittent-mild persistent cate-
gory according to GINA guidelines. The chest wheeze of
patients in studied group significantly reduced after two
month's treatment. The amount and types of drugs in the
treatment regimen of the intervention patients were
decreased as a result of improvement in asthma severity.
All patients in this group were better educated about their
asthma, were able to use their inhaler correctly and were
able to achieve almost normal daily activity levels by the
end of the study. In contrast, only minimal changes were
observed in symptom score and chest wheeze PFT values
in the usual care group.
Table 2: Asthma symptoms and severity in usual care and intervention groups of patients at the beginning, middle and the end of the 
study
Beginning Middle End
Symptoms Usual care Gr. Intervention Gr. Usual care Gr. Intervention Gr. Usual care Gr. Intervention Gr.
Night wheezing 2.12 ± 0.90 1.73 ± 0.92
NS
1.50 ± 0.98 0.50 ± 0.58
***
2.00 ± 0.98 0.19 ± 0.40
***
Night coughing 1.67 ± 1.09 1.81 ± 1.17
NS
1.08 ± 0.83 0.42 ± 0.64
**
1.25 ± 1.07 0.15 ± 0.37
***
Exercising W and C 2.04 ± 0.85 1.81 ± 0.85
NS
1.50 ± 0.83 0.73 ± 0.60
***
1.79 ± 0.83 0.27 ± 0.45
***
Morning W and C 1.50 ± 1.06 1.42 ± 1.03
NS
1.08 ± 093 0.38 ± 0.64
**
1.21 ± 1.02 015 ± 0.37
***
Daily
W and C
1.79 ± 1.02 1.88 ± 0.86
NS
1.54 ± 1.02 0.42 ± 0.64
***
1.63 ± 0.88 0.16 ± 0.37
***
Weekly
W and C
5.79 ± 2.25 5.23 ± 1.90
NS
4.67 ± 1.97 1.38 ± 1.17
***
5.46 ± 2.06 0.35 ± 0.56
***
Chest wheezing 2.33 ± 0.76 2.19 ± 0.63
NS
1.83 ± 0.76 0.54 ± 0.65
***
2.13 ± 0.80 0.31 ± 0.47
***
Asthma severity 2.67 ± 1.01 2.23 ± 0.82
NS
2.38 ± 0.88 1.11 ± 0.52
***
2.54 ± 1.02 1.00 ± 0.40
***
Gr.: group, W: wheezing, C: coughing. All values were quoted as mean ± SEM. Statistical difference in different parameter between usual care and 
intervention group: NS; non significant difference, **; p < 0.005, ***; p < 0.001.BMC Pulmonary Medicine 2008, 8:26 http://www.biomedcentral.com/1471-2466/8/26
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Comparison of symptom score of usual care (a) and intervention (b) groups of asthmatic patients at the beginning (fine filled  bars), middle (medium filled bars) and at the end (coarse filled bars) of a two month study period Figure 1
Comparison of symptom score of usual care (a) and intervention (b) groups of asthmatic patients at the begin-
ning (fine filled bars), middle (medium filled bars) and at the end (coarse filled bars) of a two month study 
period. Statistical difference in different parameter between three visits: NS; non significant difference, *; p < 0.05, **; p < 0.01, 
***, p < 0.001.
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Comparison of severity of asthma according to GINA guidelines, frequency of asthma symptoms/week and chest wheeze of  usual care (a) and intervention (b) groups of asthmatic patients at the beginning (fine filled bars), middle (medium filled bars)  and at the end (coarse filled bars) of a two month study Figure 2
Comparison of severity of asthma according to GINA guidelines, frequency of asthma symptoms/week and 
chest wheeze of usual care (a) and intervention (b) groups of asthmatic patients at the beginning (fine filled 
bars), middle (medium filled bars) and at the end (coarse filled bars) of a two month study. Statistical difference in 
different parameter between three visits: NS; non significant difference, *; p < 0.05, **; p < 0.01, ***, p < 0.001.
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At the start of the study, the PFT values, symptoms score,
asthma severity and chest wheeze tended to be worse in
the usual care group compared to the intervention group,
though these differences did not achieve statistical signif-
icance. This tendency may have reflected a slightly more
severe level of disease and a greater expectation of treat-
ment benefit in the usual care group. Thus, the short term
improvement noted in the usual care group at the second
visit, which were smaller in magnitude to that seen in the
intervention group and were reversed by the third visit,
were probably a placebo effect
The score of asthma symptoms used in the present study
was based on questionnaires used in our previous studies
(References 3, 4, 7, 8, 9 and 16). The preparation of the
questionnaire was described in our previous study (Refer-
ence 4). Briefly, a questionnaire in the Farsi language was
designed in accordance with several previous question-
naires and based on the definition of asthma used in the
Global Initiative for Asthma.
Several previous studies have demonstrated the efficacy of
applying various guidelines in the management of
asthma. For example it has been shown that the regular
measurement of PEF can lead to reduction of drug use in
asthmatic patients, specially of bronchodilators and corti-
costeroids, [12,13], reduction of asthma symptoms and
increase in PFT values [14], and better prediction of
asthma attack [15]. It has also been suggested that regular
PEF measurement is useful for determining the drug regi-
men in asthmatic patients [15]. Taken together, the above
studies emphasize the benefit of employing standard
guidelines in management of asthma.
However, in undeveloped and developing countries
guidelines are poorly applied. Our previous studies
showed that most asthmatic patients in Iran were not well
treated and were not able to administer their inhaler drugs
correctly [3,4,7,9,16]. Dashash and Mukhtar [17] also
showed that in Saudi Arabia prescribing for asthmatic
children did not conform to national guidelines for treat-
ment of asthma. They recommend increasing the use of
current asthma management guidelines by practitioners.
In another study Hijazi et al showed that patient manage-
ment is deficit in Kuwait, documentation was inadequate
and adherence to the international guidelines was partial
[18]. Other studies also suggest that major efforts should
be directed to applying guidelines in the management of
asthma [19].
Few studies have previously tested the effect of applying
guidelines in the management of asthma in countries of
our region. Alamoudi [20] examined the efficacy of a
management protocol in reducing emergency visits and
hospitalizations in chronic asthmatics. A reduction in
emergency visits and hospitalizations of chronic asthmat-
ics was demonstrated, irrespective of severity, by employ-
ing a simple protocol consisting of corticosteroids
inhalation as a monotherapy and correction of the inha-
lation technique. Our previous studies also showed that
regular PEF measurement and using rescue salbutamol
inhaler at the time of chest tightness leads to improve-
Table 3: Pulmonary function tests (PFTs) in usual care and intervention groups of asthmatic patients at the beginning, middle and the 
end of the study
Beginning Middle End
PFTs Usual care Gr. Intervention Gr. Usual care Gr. Intervention Gr. Usual care Gr. Intervention Gr.
FVC 57.71 ± 10.57 61.50 ± 11.77
NS
65.88 ± 16.27 79.12 ± 7.35
***
59.71 ± 10.10 81.35 ± 10.16
***
FEV1(l) 56.88 ± 14.27 59.00 ± 9.57
NS
61.46 ± 16.23 80.19 ± 10.93
***
55.29 ± 12.64 82.65 ± 10.50
***
PEF(l/s) 45.04 ± 13.71 51.92 ± 17.43
NS
45.79 ± 12.05 66. 96 ± 13.21
***
42.75 ± 11.28 73.46 ± 12.04
***
MMEF 42.58 ± 17.04 45.61 ± 10.73
NS
43.83 ± 17.11 76.88 ± 15.18
***
40.54 ± 14.05 81.12 ± 15.40
***
MEF75(l/s) 41.38 ± 15.77 52.04 ± 18.21
*
44.17 ± 12.54 67.31 ± 14.75
***
40.83 ± 9.85 73.73 ± 13.92
***
MEF50(l/s) 44.13 ± 13.56 49.23 ± 16.23
NS
44.42 ± 14.21 78.31 ± 17.31
***
40.75 ± 12.03 87.31 ± 18.26
***
MEF25(l/s) 49.92 ± 19.40 51.77 ± 15.37
NS
48.17 ± 18.65 86.81 ± 25.28
***
42.63 ± 14.08 86.96 ± 22.23
***
Gr.: group, FEV1: forced expiratory volume in one second; FVC: forced vital capacity; PEF: peak expiratory flow; MMEF: maximal mid expiratory 
flow; MEF75, MEF50 and MEF25: maximal expiratory flow at 75%, 50%, and 25% of the FVC respectively. All values of PFTs were quoted as mean ± SD 
of percentage predicted. Statistical difference in different parameter between usual care and intervention groups: NS; non significant difference, *; p 
< 0.05, **; p < 0.005, ***; p < 0.001.BMC Pulmonary Medicine 2008, 8:26 http://www.biomedcentral.com/1471-2466/8/26
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Comparison of pulmonary function tests of usual care (a) and intervention (b) groups of asthmatic patients at the beginning  (fine filled bars), middle (medium filled bars) and at the end (coarse filled bars) of a two month study Figure 3
Comparison of pulmonary function tests of usual care (a) and intervention (b) groups of asthmatic patients at 
the beginning (fine filled bars), middle (medium filled bars) and at the end (coarse filled bars) of a two month 
study. FEV1: forced expiratory volume in one second; FVC: forced vital capacity; PEF: peak expiratory flow; MMEF: maximal 
mid expiratory flow; MEF75, MEF50 and MEF25: maximal expiratory flow at 75%, 50%, and 25% of the FVC respectively. All val-
ues of PFTs were quoted as percentage predicted. Statistical difference in different parameter between three visits: NS; non 
significant difference, *; p < 0.05, **; p < 0.01, ***, p < 0.001.
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ment in FEV1 and PEF, reduction in symptom score,
asthma attack and in rescue inhaled salbutamol use [7].
In addition to this, we have previously shown that most
asthmatic patients in Iran did not receive adequate knowl-
edge regarding avoidance of risk factors and of acceptable
treatment regimens. The addition of a standard treatment
plan in asthmatic patients led to improvement in symp-
tom score and PFT values [8]. We have also previously
emphasised that education is an important and necessary
step in the efficacy of inhaler drugs. Most asthmatic
patients did not receive adequate instruction regarding the
inhalation technique and were not able to use their
inhaler correctly; once fully educated in this regard, salb-
utamol inhalation by the inhaler alone was as effective as
using it with a spacer. [9].
The application of GINA guideline 2002 in treating asth-
matic patients showed significant improvement in asthma
therapy. Therefore, the application of GINA guideline
2006 my resulted in greater improvement in treating asth-
matic patients. In addition, in the present study patients
were studied for relatively short period of time (2 months)
and treating patients for longer period could lead to better
results. However in this study period, there was significant
improvement in treatment of patients. This may be due to
education and style deficiency in treating asthmatic
patient in our country.
Although the questionnaire used in the present study was
validated in the previous studies [7,8,10], there are some
limitation in this study including using version 2002 of
GINA guidelines in the study and therefore the data are
not new. The treatment received by the participants was
also a bit heterogeneous which is the nature of treatment
regimen of the patients in developing countries. The QoL
Table 4: Different type of drugs in treatment regimen in usual care and intervention groups of asthmatic patients at the beginning, 
middle and the end of the study 
Type of Beginning Middle End
Drugs Usual care Gr. Intervention Gr. Usual care Gr. Intervention Gr. Usual care Gr. Intervention Gr.
Inhaler salbotamol 75.00 66.70 83.00
NS
92.50
***
79.20
NS ns
73.10
NS +++
Oral salbotamol 29.2 26.90 16.65
NS
15.40
*
25.00
NS ns
3.80
*** ++
Inhaler Salmetrol 0 3.80 20.8
***
19.20
***
4.2
NS +++
15.40
** ns
Inhaler corticosteroid 25.00 26.90 62.50
***
88.50
***
41.7
* ++
30.80
NS +++
Oral corticosteroid 25.00 26.90 29.20
NS
42.30
*
20.80
NS ns
7.70
*** +++
Oral theophylline 50.00 53.85 83.00
***
76.90
*
54.20
NS +++
15.40
*** +++
Anti-histamine 8.30 15.40 33.3
***
30.80
*
8.30
NS +++
19.20
NS +
Inhaler using technique 41.70 30.80 45.80
NS
100
***
45.80
NS ns
100
*** ns
(percentage of total patients in each group)
Statistical difference in the percentage of patients using each type of drug between beginning with middle and the end of the study: NS; non 
significant difference, *; p < 0.05, **; p < 0.005, ***; p < 0.001. Statistical difference in the percentage of patients using each type of drug between 
middle and the end of the study: ns; non significant difference, +; p < 0.05, ++; p < 0.005, +++; p < 0.001. The dose of beclomethasone dipropionate 
in patients of both groups was 400–1400 μg depending upon the severity of the disease and the dose of fluticasone dipropionate was 500 μg.
Table 5: Number and percentage of two groups of asthmatic 
subjects under combination therapy and different type of drugs 
used and percentage of patients using each type of drug
Type of Drugs Usual care Gr. Intervention Gr.
Beginning End Beginning End
n% n % n% n%
OBA+OCS+OT+IBA 6 25.0 5 20.8 7 27.0 1 3.8
OCS+OT+IBA 0 0.0 0 0.0 0 0.0 1 3.8
OBA+ OT+IBA +ICS 1 4.2 1 4.2 0 0.0 0 0.0
OT+IBA 0 0.0 5 20.8 5 19.2 0 0.0
OT+IBA+ ICS 5 20.9 2 8.3 2 7.7 2 7.7
LAIBA+ICS 0 0.0 1 4.2 1 3.8 4 15.4
IBA+AH 2 8,3 2 8.3 0 0.0 3 11.5
IBA+ ICS 0 0.0 2 8.3 0 0.0 1 3.8
AH+ICS 0 0.0 0 0.0 4 15.4 2 7.7
ICS only 0 0.0 2 8.3 0 0.0 1 3.8
IBA only 4 16.7 2 8.3 3 11.5 11 42.0
n: number, %: percentage of patients using each type of drug, OBA; 
oral beta agonist, OCS; oral corticosteroid, OT; oral theophylline, 
IBA; inhaled beta agonist, ICS; inhaled corticosteroid, LAIB; long 
acting inhaled beta agonist, AH; anti histaminePublish with BioMed Central    and   every 
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should be 'evaluated by an international validated ques-
tionnaire. However, the results of the study are interesting
and therefore further studies need to be performed
according new version of GINA guideline and using inter-
national validated questionnaire in devolving countries.
Conclusion
The present study extends the findings of our previous
studies by demonstrating the suitability of adopting GINA
guidelines in the management of asthma in countries of
our region. The demonstration of significant improve-
ments in asthma symptoms (specially chest wheeze),
severity, drug usage, inhalation technique, and PFT values
after applying GINA guidelines is promising. However,
further studies are needed with greater numbers of
patients with a wider range of disease severity. The long
term benefits will also need to be tested by monitoring the
effects over a longer period.
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